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1. Introduction
As a middle-income country with a limited healthcare budget, South 
Africa (SA) faces many challenges. The country is making huge 
efforts to meet the Millennium Development Goals, specifically goals 
4 and 5. Maternal and child health represents an important priority 
to improve morbidity and mortality rates.
Surviving premature infants have many unique healthcare 
needs, including screening for retinopathy of prematurity (ROP). 
The importance of this screening cannot be underestimated, as 
early detection and treatment reduces blindness and permanent 
disability.
SA has become part of the so-called ‘third epidemic of ROP’, 
with an increasing incidence as more premature infants survive due 
to improved neonatal care. As in other middle-income countries, 
infants with higher birth weights are at risk of ROP because 
treatment units may not have the skills or equipment to monitor 
oxygen appropriately. Resources may also be inadequate to identify 
at-risk infants.1
Each year >1 million babies are born in SA; 87% in the public 
healthcare sector, including almost half in district-level facilities, 
10% in clinics or community health centres, and 38% in district 
hospitals. An equal number of neonates are delivered in facilities with 
specialist-run services; 32% in regional hospitals and 20% in tertiary 
and central hospitals.2
Data suggest that 12.8% of babies born in the public sector have 
a birth weight <2 500 g.2 As the sector has limited facilities, few 
newborns have access to appropriate care. While public health and 
infrastructure interventions aim to improve facilities to ensure 
equitable access to care, such improvements take time. Even if 
these plans are realised, a mismatch in services for babies at risk of 
ROP will persist. Neonatal intensive care units (NICUs) are to be 
established in tertiary and regional hospitals, where ophthalmology 
expertise is often not available. Approximately 16 000 babies are 
at risk of ROP and require screening each year.1 These disparate 
services necessitate innovative responses in the implementation of 
screening programmes to successfully minimise the consequences 
of ROP.
Studies in SA academic institutions have shown an acceptably low 
ROP incidence.3 However, these centres have appropriate neonatal 
care facilities and adequate resources to screen high-risk infants.4-6 
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S Afr Med J 2013;103(2):116-125. DOI:10.7196/SAMJ.6305
117  February 2013, Vol. 103, No. 2  SAMJ
Larger, well-resourced centres may follow guidelines such as those 
of the American Academy of Pediatrics and the Royal College of 
Ophthalmologists. However, these guidelines may not be appropriate 
in under-resourced centres. Rather, guidelines proposed in other 
middle-income regions may be more fitting, e.g. those from South 
East Asia and Central/South America, where larger, more mature 
infants at risk have been identified.7
Barriers to screening must also be overcome,8 including: the need 
to travel to a treatment/screening centre; the affordability and time-
constraints of taking infants elsewhere for further screening; and loss 
to screening/follow-up programmes.
An absolute shortage of ophthalmologists in SA compounds 
the problem. The few appropriately trained state-employed 
ophthalmologists are based mainly in the larger urban centres. 
In remote areas, new technologies such as digital photographic 
screening devices may offer remote screening via telemedicine. 
However, these electronic devices are expensive and require a trained 
technician to capture and transmit the images for evaluation.9
This 2012 consensus guideline, developed by paediatricians, 
neonatologists and ophthalmologists in SA public and private 
practice, has been endorsed by the United South African Neonatal 
Association (USANA), the Ophthalmological Society of South 
Africa (OSSA), and the South African Vitreoretinal Society. It is 
intended to guide the screening and appropriate neonatal care of 
infants at risk of ROP.
2. Oxygen saturation guideline after birth 
Different centres in different countries report a varying incidence 
of severe ROP. The altered regulation of vascular endothelial 
growth factor from repeated episodes of hyperoxia and hypoxia is 
one important factor in ROP pathogenesis. Strict management of 
oxygen delivery and monitoring to minimise these episodes may be 
associated with decreased rates of ROP.
Oxygen is the most commonly used ‘drug’ in neonatal units. It 
is well documented that it is easy to damage the eyes of preterm 
infants by administering too much oxygen, especially in the first 
few weeks of life. Studies have shown a relationship between oxygen 
administration and the development of ROP.10-12 In animal models, 
repeated cycles of hyperoxia and hypoxia were shown to produce 
more retinal neovascularisation than hypoxia or hyperoxia alone.13 
In the early 1990s, an increased incidence of severe ROP was 
shown in premature infants in the first several weeks of life with a 
transcutaneous oxygen tension (tcPO2) ≥80 mmHg.14
In the first weeks of life, lower oxygen saturation (SaO2) targets 
in preterm infants reduce ROP and pulmonary complications and 
may improve growth. Data from NICUs in Northern England15 
identified 4 oxygen policies in neonates according to SaO2 limits 
that were set at: (i) 70 - 90%; (ii) 84 - 94%; (iii) 85 - 95%; and (iv) 
88 - 98%. The occurrence of ROP requiring cryotherapy (threshold 
ROP (tROP)) was 4 times higher in the high SaO2 group (88 - 98%) 
compared with the low SaO2 group (70 - 90%). This was confirmed 
in a study which found that neonates nursed in SaO2 >92% had 
more severe ROP than babies nursed in SaO2 <93%.16
The Australian Benefits Of Oxygen Saturation Targeting (BOOST) 
trial compared an SaO2 of 91 - 94% v. 95 - 98% in neonates.17 While 
no difference was found in long-term development, there was 
an increase in the duration of oxygen therapy, an increase in the 
occurrence of home oxygen therapy, and more frequent chronic lung 
disease in the high SaO2 group. High SaO2 targets therefore have a 
detrimental effect on the lungs and the eye. 
The unexpected finding of excess deaths from pulmonary causes 
among infants in the high SaO2 group – albeit not statistically 
significant – accords with the findings of the only other trial in 
which preterm infants were randomly assigned to different target 
SaO2 ranges – namely the Supplemental Therapeutic Oxygen for 
Prethreshold Retinopathy of Prematurity (STOP-ROP) trial.18 The 
trial showed an increased rate of adverse pulmonary sequelae 
(although not an increased rate of death due to pulmonary causes) 
among preterm infants with pre-tROP when a higher SaO2 range 
(96 - 99%) was targeted.
Chow et al.19 emphasised the importance of avoiding peaks in SaO2 
and the constant training of staff to keep the saturation within strictly 
defined limits. Oxygen toxicity, particularly in preterm infants, can 
inhibit lung healing and contribute to ongoing lung injury.20
A meta-analysis of the association between SaO2 measured by pulse 
oximetry and risk of severe ROP indicated a statistically significant 
risk reduction of 52% with low SaO2 (70 - 96%) in the first postnatal 
weeks and 46% with high SaO2 (>94 - 99%) at a postmenstrual age 
(PMA) of ≥32 weeks.21 The analysis revealed that high SaO2 has 
different effects at postnatal points that correspond roughly to the 
first and second phases of ROP.
High partial oxygen pressure (PaO2) occurs very rarely in neonates 
breathing supplemental oxygen when pulse SaO2 values are 85 - 93%. 
This pulse SaO2 range also is infrequently associated with low PaO2 
values. Pulse SaO2 values of >93% are frequently associated with PaO2 
values >80 mmHg, which may be of risk for some newborns receiving 
supplemental oxygen.22
The optimal SaO2 is not known in infants of extremely low birth 
weight, but data indicate that it should be kept at ≤93%. In the 
SUPPORT trial, a target SaO2 range of 85 - 89%, compared with 91 
- 95%, did not affect the combined outcome of severe ROP or death. 
However, it increased mortality while substantially decreasing severe 
ROP among survivors. Caution should be exercised in targeting 
levels of SaO2 in the low range for preterm infants, as it may lead to 
increased mortality.23 Many centres therefore aim for saturations of 
88 - 92%. Fluctuations with peaks in SaO2 should be avoided.
Table 1 lists clinical trials which compared outcome parameters in 
infants according to higher and lower SaO2 groups.
Table 2 summarises the characteristics of studies that assessed the 
association between high SaO2 and severe ROP risk among preterm 
infants in the first several weeks of life. Meta-analysis of the pooled 
estimates showed a significantly decreased risk of ROP with lower SaO2 
(relative risk (RR) 0.48; 95% confidence interval (CI) 0.31 - 0.75).
Table 3 summarises the characteristics of studies that evaluated 
the association between SaO2 and severe ROP risk after a PMA ≥32 
weeks in preterm infants. Meta-analysis of the pooled estimates 
showed a statistically significant RR of 0.54 (95% CI 0.35 - 0.82). 
In a meta-analysis of high or low oxygen saturation and severe 
ROP, Chen et al.21 concluded that low SaO2 (70 - 96%) in the first 
several postnatal weeks was associated with a reduced risk of severe 
ROP (RR 0.48; 95% CI 0.31 - 0.75) and high SaO2 (94 - 99%) after a 
PMA of 32 weeks was associated with a decreased risk for progression 
to severe ROP (RR 0.54; 95% CI 0.35 - 0.82).21
Currently, the ongoing Neonatal Oxygen Prospective Meta-
analysis (NeOProM) study is questioning whether targeting a lower 
oxygen range in extremely premature neonates increases or decreases 
the composite outcome of death or major disability in survivors by 
≥4%.The results of the study will be available in 2014. 
All neonates receiving supplemental oxygen (ventilator, 
continuous positive airways pressure (CPAP), nasal prongs or 
head box oxygen) should be monitored with a pulse oximeter 
and SaO2 should be recorded. Oxygen should be humidified. An 
oxygen saturation guideline (Appendix I) should be displayed in 
the neonatal ICU.
GUIDELINE
118  February 2013, Vol. 103, No. 2  SAMJ
3. Screening protocol
ROP is a disorder of the developing retina of preterm infants that 
potentially leads to blindness in a small but significant percentage. 
ROP cannot occur in term neonates, as the retina is fully developed. 
The disease is a preventable cause of blindness if supplemental oxygen 
therapy is used appropriately, and a screening programme is in place 
for preterm neonates who have received such therapy. An effective goal 
of a screening programme is to identify the preterm infants at risk of 
ROP and who require treatment (from the much larger number of 
at-risk infants), while minimising the number of stressful examinations 
required for these sick infants. Any screening programme designed to 
implement an evolving standard of care has inherent defects such as 
over-referral or under-referral, and by its nature, cannot duplicate the 
precision and rigor of a scientifically based clinical trial.
The recommendations for screening are modified from the 
guidelines of the American Academy of Pediatrics and those of the 
United Kingdom. In SA, most pregnant mothers do not know their 
gestation, and gestational age assessment is not accurate. It is therefore 
recommended that weight rather than gestational age is used for 
screening high-risk preterm neonates. There are few studies regarding 
the incidence of ROP in sub-Saharan Africa. An early study of children 
in schools for the blind in SA revealed that 10.6% of blindness was 
due to ROP; only 1.25% of this was in black children.33 Kirsten et 
al.6 reported a 30% frequency of ROP (7% with stage 3 or worse) 
in a multiracial study population. Delport et al.5 reported an ROP 
frequency of 24.5% in a hospital treating predominantly black patients 
(Kalafong), with 6.4% developing stage 3 ROP and 4.2% requiring 
treatment (including 1 neonate with a birth weight >1 250 g).
The incidence of childhood blindness due to ROP in certain Latin 
American and Eastern European countries has been reported to be 
as high as 38.6% and 25.9%, respectively.33 The incidence of ROP 
in a Vietnamese study34 was 45.8% in neonates weighing <2 000 g 
and 81.2% in babies weighing <1 250 g. In total, 25% of the babies 
weighing <1 250 g developed tROP.
Table 1. Prospective clinical trials comparing outcome parameters in infants dichotomised into high and low SaO2 groups*
Study Subject population SaO2 groups Survival CLD ROP 3 - 4 ROP therapy
Tin et al.15 <27 weeks Low (70 - 90%) 53% 18%   6%





≤1 500 g Low (≤92%) 83% 27% 10% 4%








≤1 500 g Low (≤92%)     5.7% 1.4%






500 - 1 500 g Low (85 - 93%) 88%   2.5% 0 - 1.3%






<30 weeks Standard (91 - 94%) 97% 46% 16% 11%
≤32 weeks High (95 - 98%) 95% 64%
(p<0.001)
12% 6%
*Adapted from Tin et al.32
†Randomisation after 32 weeks. Survival after randomisation. CLD = chronic lung disease














Wright et al.24 Prospective 1998 - 2002 <30 500 - 1 500 350 Immediate post-
gestation life
Low (83 - 93) v. 
high (89 - 95)
1.3 v. 7.3
Wallace et al.25 Retrospective 2002 - 2005 ≤30 <1 250 105 First 6 weeks Low (90 - 96) v. 
high (98 - 100)
14.0 v.
18.0
Van der Veen et al.26 Retrospective 2000 - 2003 ≤28 <1 250 323 First 4 weeks Low (85 - 93) v. 
high (87 - 97)
5.6 v. 17.5
Tin et al.15 Prospective 1990 - 1994 <28 810 - 1 074 295 First 8 weeks Low (70 - 94) v. 
high (85 - 98)
8.8 v. 19.7
Deulofeut et al.27 Prospective 2000 - 2004 26 - 27 
(mean)
<1 250 373 Started at birth Low (85 - 93) v. 
high (92 - 100) 
4.0 v. 7.0
tROP = threshold ROP; SaO2 = saturation oxygen.
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A large prospective study of ROP at Chris Hani Baragwanath 
Academic Hospital (CHBAH), Soweto – a tertiary referral centre for 
indigent South Africans4 – reported a 2.5% overall occurrence rate 
of stage 3 ROP. Those with tROP requiring treatment represented 
1.6% of the total cohort. No tROP was observed in neonates weighing 
>1 250 g at birth, but many patients with ROP were lost to follow-up 
before witnessing progression or regression of tROP. The SA studies 
have been among small cohorts in tertiary centres. Multicentre studies 
must be performed to establish the actual incidence of ROP. Most 
level 2 hospitals admit preterm neonates who are given supplemental 
oxygen. These facilities do not perform ROP screening due to a lack 
of resources and shortage of ophthalmologists. A screening guideline 
must be implemented in level 2 centres, to identify and appropriately 
refer at-risk neonates. 
3.1 Screening guideline
3.1.1 Who to screen
• All neonates born prior to 32 weeks’ gestation
• All preterm neonates weighing <1 500 g.
• Preterm infants weighing 1  500 - 2  000 g may also be at risk 
of ROP if they have risk factors such as: a family history of 
ROP, cardiac arrest, multiple (>2) blood transfusions, exchange 
transfusion or severe HIE. If their oxygen monitoring has been 
suboptimal, then screening can be considered if resources allow, 
but ensuring appropriate oxygen monitoring is more cost-
effective.
3.1.2 When to screen
• Screening should be performed at 4 - 6 weeks chronological age 
or 31 - 33 weeks post-conceptional age (whichever comes later). If 
gestational age is unknown, then chronological age should be used.
• Threshold is usually reached by 37 weeks – it is therefore important 
to assess the baby before 37 weeks post-conceptional age.
• After the initial screening, follow-up for ROP will be determined 
by the ophthalmologist.
3.1.3 Where to screen
• Outpatient screening should be performed in a facility capable of 
caring for a child who develops apnoea during the examination 
and where ophthalmological services are available. Where 
there is limited access to ophthalmologists, other screening 
modalities (such as photographic screening – see below) may 
be considered.
• A guide for screening for ROP (Appendix II) should be 
displayed in the neonatal ICU.
3.1.4 Preparation of the infant for screening
• Benoxinate (local anaesthetic): apply 1 drop to each eye at the 
outset
• Cyclomydril (2 mg cyclopentolate hydrochloride, 10 mg 
phenylephrine hydrochloride) (to dilate the pupils): apply 1 
drop to each eye every 15 - 20 min, commencing approximately 
45 minutes prior to the eye examination, until the pupil is 
dilated (an average of 3 drops)
• Chlorampenicol (topical antibiotic): apply 1 drop at the end of 
the examination
• Refer to Appendices III, IV and V.
4. Guideline for ophthalmologists 
performing ROP screening
Patients should be referred to the ophthalmologist by the neonatologist 
according to the referral protocol above. Should an ophthalmologist 
not be available, photographic screening may be an option (see below).
4.1 Where to screen
To avoid physiological stress on the infant, examination should 
ideally be performed by the ophthalmologist in the neonatal unit with 
appropriate monitoring, as guided by the treating neonatal healthcare 
professionals. Should this not be possible, personnel and equipment 
needed for neonatal resuscitation should be easily accessible to the 
ophthalmologist at the time of examination. 
4.2 How to screen
• The discomfort and systemic effect of the examination should 
be minimised by pre-treatment of the eyes with a topical 
anaesthetic agent such as proparacaine or benoxinate.
• The use of pacifiers or oral sucrose may be considered.
• Pupils should be dilated with Cyclomydril drops, applied 
every 15 - 20 minutes (1 drop to each eye, commencing 45 - 
60 minutes prior to the eye examination – refer to Appendices 
III, IV and V).
• Examination must be performed by a qualified examiner using 
binocular indirect ophthalmoscopy (Appendix VI).
• Detailed notes should be kept (e.g. see Appendix VII).
• In the absence of qualified examiners, photographic screening 
should be done.














McGregor et al.28 Prospective 
cohort
1996 - 1999 26.2±1.8 
(mean)
Unknown 365 36.7±2.5 (mean 
PMA)
High (>94) v. 
low (≤94)
25 v. 46
STOP-ROP group18 RCT 1994 - 1999 25.4±1.5 
(mean)
726±160 649 35.4±2 (mean 
PMA)
High (96 - 99) 
v. low (89 - 94)
41 v. 48
Gaynon et al.29 Retrospective 
cohort
1985 - 1993 26 - 27 
(mean)
814 - 986 153 36 - 38 (+9 - ~10) 
(mean PMA)
High (99) v. 
low (92 - 96)
7 v. 37
Askie et al.17 RCT 1996 - 2000 <30 917 358 32 (+1) - ~10 
(PMA)
High (95 - 98) 
v. low (91 - 94)
12 v. 16
Seiberth et al.30 Cohort 1994 - 1996 24 - 32 Unknown 117 33 - 42 (PMA; 
ROP stage 3)
High (≥98) v. 
low historic
1.8 v. 4.2
SaO2 = saturation oxygen; tROP = threshold ROP; RCT = randomised controlled trial; PMA = postmenstrual age; STOP-ROP = Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity study.
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4.3 How to follow-up and manage
Follow-up examinations should be recommended by the examining 
ophthalmologist on the basis of retinal findings classified according 
to international classification35 (Appendix VIII). The following 
schedule is suggested: 
• 1 week or less follow-up
• Stage 1 or 2 ROP in zone I 
• Stage 3 ROP in zone II
• 1 - 2 weeks follow-up
• Immature vascularisation in zone I (no ROP) 
• Stage 2 ROP in zone II 
• Regressing ROP in zone I
• 2 weeks follow-up
• Stage 1 ROP in zone II 
• Regressing ROP in zone II
• 2 - 3 weeks follow-up
• Immature vascularisation in zone II (no ROP) 
• Stage 1 or 2 ROP in zone III 
• Regressing ROP in zone III.
The presence of plus disease (defined as dilation and tortuosity 
of the posterior retinal blood vessels) in zones I or II suggests that 
peripheral ablation, rather than observation, is appropriate.36
Practitioners involved in the ophthalmological care of preterm 
infants should be aware that the retinal findings that require 
strong consideration of ablative treatment were revised according 
to the Early Treatment for Retinopathy of Prematurity (ETROP) 
randomised trial.37 The identification of tROP, as defined in the 
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity 
(CryoROP), may no longer be the preferred time of intervention. 
Treatment may also be initiated for the following retinal findings: 
• Zone I ROP: any stage with plus disease 
• Zone I ROP: stage 3, no plus disease 
• Zone II ROP: stage 2 or 3 with plus disease.
Special care must be taken in determining the zone of 
disease. The number of clock hours of disease may no longer 
be the determining factor in recommending ablative treatment. 
Treatment should generally be accomplished, when possible, 
within 72 hours of determination of treatable disease to minimise 
the risk of retinal detachment.
4.4 When to stop screening
The conclusion of acute retinal screening examinations should be 
based on age and retinal ophthalmoscopical findings.36 Findings that 
suggest that examinations can be curtailed include: 
• Zone III retinal vascularisation attained without previous zone 
I or II ROP (if the examiner doubts the zone or if the 
postmenstrual age is <35 weeks, confirmatory examinations 
may be warranted)
• Full retinal vascularisation
• Postmenstrual age of 45 weeks and no pre-threshold disease (stage 
3 ROP in zone II, any ROP in zone I) or worse ROP is present
• Regression of ROP38 (care should be taken to ensure that no 
abnormal vascular tissue is present that is capable of reactivation 
and progression).
5. General information
It is very important that healthcare staff members communicate with 
guardians. Guardians should be made aware of ROP examinations 
and be informed if their child has ROP, with subsequent updates on 
ROP progression. The possible consequences of serious ROP should 
be discussed at the time that a significant risk of poor visual outcome 
develops. Documenting such conversations with parents in the nurse 
or doctor notes is highly recommended. 
If hospital discharge or transfer to another neonatal unit or 
hospital is contemplated before retinal maturation into zone III 
has occurred, or if the infant has been treated by ablation for ROP 
and is not yet fully healed, then the availability of an appropriate 
follow-up ophthalmological examination must be ensured. Specific 
arrangements for that examination must be made before discharge 
or transfer. The transferring primary doctor, after communication 
with the examining ophthalmologist, should be responsible for 
communicating which eye examinations are needed and their 
required timing to the infant’s new primary doctor. The latter should 
ascertain the ocular examination status of the infant from the record 
and via communication with the transferring doctor. Necessary 
examinations by an ophthalmologist experienced in examining 
preterm infants for ROP can thereby be arranged promptly at the 
receiving facility, or as an outpatient if discharge is contemplated 
before the need for continued examination has ceased.
If guardians are delegated responsibility for arranging follow-up 
ophthalmological care after discharge, then they should understand: 
the potential for severe visual loss, including blindness; that there 
is a critical time window to be met for treatment success; and that 
timely follow-up examination is essential to successful treatment. 
This information should preferably be communicated verbally and in 
writing (Appendix IX). If such arrangements for communication and 
follow-up after transfer or discharge cannot be made, then the infant 
should not be transferred or discharged until an appropriate follow-
up examination can be arranged by the discharging unit.
6.  Telemedicine screening and 
monitoring of ROP
A lack of skilled personnel to perform screening often restricts both 
the screening and management of ROP. Proposed revisions in the 
management of high-risk pregnancies, the improvement in neonatal 
survival and the development of new neonatal units may dramatically 
increase the number of premature infants requiring screening. The 
ability to offer a comprehensive screening service at all hospitals 
in which neonates at risk are managed may be limited by a lack of 
suitably trained paediatric ophthalmologists.
The advantages of telemedicine screening in ROP39-43 include 
the ability to train neonatal nursing staff, medical officers and 
optometrists to capture and transmit screening photographs to a 
suitably trained ophthalmologist for assessment.
Use of the digital wide-field retinal imaging Retcam II is well 
described for ROP screening. The Retcam has the advantage over 
other digital retinal imaging systems in being a hand-held contact-
based camera that is suitable for use in neonatal units or operating 
theatres and does not require patient co-operation or a seated 
position. Studies have confirmed the sensitivity and specificity of 
the Retcam, and its use is a safe, effective alternative for providing 
Table 4. Pulse oximeter saturation guideline for preterm 










6.5 - 9.0 50 - 70 88 - 92% 86 - 94%
CLD and 36 
weeks PMA
8.0 - 10.0 60 - 75 90 - 95% 88 - 96%
PaO2 = partial oxygen pressure, CLD = chronic lung disease
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screening where appropriate ophthalmologists are not available. The 
Retcam is also widely used to document disease management and 
response to treatment.
7. Conclusion
ROP is a preventable disease. Optimal management of oxygen 
therapy is the most important preventive measure. Every unit which 
cares for preterm neonates should have protocols and guidelines on 
oxygen therapy and SaO2 targets in neonates. Timeous referral to 
the ophthalmologist for ROP screening is important to enable early 
diagnosis and treatment of ROP in preterm infants weighing <1 500 g 
and in larger unstable preterm infants where oxygen monitoring and 
management has been suboptimal.
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Appendix I. Oxygen saturation 
guideline*
Pulse oximeter saturation guideline for preterm 
neonates receiving supplemental oxygen
(i)   Babies receiving or likely to require supplemental oxygen 
should be monitored by continuous pulse oximetry. 
(ii)  All neonates receiving supplemental oxygen (ventilator, 
CPAP, nasal prongs or head box oxygen) should be monitored 
with a pulse oximeter and saturation should be recorded. 










6.5 - 9.0 88 - 92% 86 - 94%
CLD and 36 
weeks PMA
8.0 - 10.0 90 - 95% 88 - 96%
PaO2 = partial oxygen pressure; PMA = postmenstrual age.
(iii)  Nasal prong oxygen therapy:flow should be 0.5 - 1 l/min. A 
blender should be used to administer oxygen.
(iv)  Head box oxygen:flow should be 2 - 3 l/kg/min. Head 
box oxygen is not recommended, but if utilised, arterial 
saturation of oxygen should be monitored with pulse 
oximetry (SpO2).
(v)   Pulse oximetry upper alarm should never be set at 100% if 
infants are receiving supplemental oxygen.
(vi)  Avoid SpO2 changes >93 - 95% in very low birth weight 
infants (VLBW) (<1 500 g).
* Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in 
extremely preterm infants. N Engl J Med 2003;349:959-967.
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Appendix II. Screening for ROP*
*Compiled by: R Singh, L Visser
Who to screen
(i) All neonates born <32 weeks gestation 
(ii) All preterm neonates weighing <1 500 g.
Note: Preterm infants weighing 1  500 - 2  000 g may also be at 
risk of ROP if they have risk factors such as: a family history of ROP, 
cardiac arrest, multiple (>2) blood transfusions, exchange transfusion 
or severe HIE. If oxygen monitoring has been suboptimal in this 
group of infants, then screening can be considered.
When to screen
• At 4 - 6 weeks chronological age or 31 - 33 weeks post-
conceptional age (whichever comes later). 
• If gestational age is accurate then neonates <28 weeks post-
conceptional age should be screened at 6 weeks after birth 
and neonates >28 weeks post-conceptional age at birth 
should be screened 4 weeks after birth. 
Where to screen
Outpatient screening should be performed in a facility capable 
of caring for a child who develops apnoea during examination. 
It should be performed wherever there are ophthalmological 
services in a cubicle in the nursery. Where there is limited 
access to ophthalmologists, other screening modalities may be 
considered (e.g. Retcam). If there is no screening facility in a 
hospital, then arrangements must be made for the neonate to be 
seen by an ophthalmologist at the nearest hospital, and the mother 
should be informed about the risks of ROP.
Follow-up
A follow-up guideline for ROP should be determined by an 
ophthalmologist after the initial screening. 
Appendix III. Preparation of infants 
for ROP screening
All requirements must be met in the morning prior to ROP 
assessment (preparation should not start when the ophthalmologist 
arrives). Requirements:
(i) All patients should be identified and dilatation should be 
started 45 minutes - 1 hour before the start of the clinic:
•  Benoxinate eye drops: apply 1 drop to each eye at the outset 
only 
•  Chloramphenicol eye drops: apply 1 drop to each eye at the 
beginning and end of examination only
•  Cyclomydril eye drops: apply 1 drop to each eye every 15 
- 20 minutes.
(ii) Working cardiac trolley, a basinet, a soft blanket for 
swaddling and a table to write on 
(iii) A dedicated staff nurse to be allocated to help during the 
procedure
(iv) A separate sterile pack with 10 ml of water for injection 
per infant
(v) Diluted Hibitane for sterilisation of speculum
(vi) All request forms should be completed by the referring doctor 
(vii) Every neonate booked for the clinic should have an ROP 
form completed in duplicate
(viii) A diary should be kept with all appointments.
Appendix IV. Prescription for eye 





Benoxinate drops: apply to each eye at the outset.
Cyclomydril drops: apply 1 drop to each eye every 15 - 20 
minutess (repeat 3 - 4 times) 
Chloramphenicol drops: apply at the end of the examination.
Doctor name and signature
Appendix V. Procedure for mydriasis 
(dilatation of the pupil)
• Infants undergoing retinal examinations should have their 
pupils dilated with a cycloplegic mydriatic agent prior to 
examination to ensure optimal evaluation of the retina.
• The following procedures should be followed to limit 
systemic absorption and related symptoms:
Procedure for administration of Cyclomydril eye drops 
prior to neonatal retinal examinations in infants (adapted 
from Tygerberg Hospital)
Step Action
1 Commence with administration of Cyclomydril eye drops 
45 mins prior to eye examination
2 Administer 1 drop of Cyclomydril eye drops into each eye 
every 20 minutes for a maximum of 3 dosages
3 Wipe excess eye drops away and apply gentle pressure over 
the nasolacrimal duct for 1 minute following instillation of 
eye drops, to prevent systemic absorption and possible side-
effects
4 Monitor infant for signs of tachycardia, restlessness, 
apnoea, desaturation and bradycardia for a minimum 
of 12 hours after commencement of Cyclomydril 
administration and report to paediatrician immediately
5 Dim lights and keep the infant’s eyes covered with an eye 
cloth for a minimum of 12 hours after commencement 
of Cyclomydril administration in order to minimise pain 
experienced due to pupil dilation
Side-effects of Cyclomydril
If any of these rare side-effects of Cyclomydril eye drops occur 
(including signs of systemic absorption), then admit the patient 
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Appendix VI. Equipment required for ROP screening
(i)  Indirect ophthalmoscope
(ii) A 20, 28 or 30 dioptre lens
(iii) Scleral depressor
(iv) Infant wire speculum with 4 mm blades
(v) Soft blanket for gentle swaddling of the infant
(vi)  An alternative method of screening is the use of a Retcam, where a wide-angle retinal camera is used by a hospital technician and the 
images are sent to the ophthalmologist to interpret the findings at a tertiary level.  
Appendix VII. ROP screening form




Birth weight (g): Multiple birth (1,2,3):
Gestational age at birth: Growth at birth – AGA/SGA/LGA:
Duration of oxygen IPPV: CPAP: Nasal O2:
Indication for ROP screening in this patient: please tick appropriate box:
☐ weight <1 500g
☐ gestational age <32 weeks at birth
☐ weight 1 500 - 2 000 g with unstable clinical course
Examination
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Appendix VII: ROP screening form (continued)
Follow-up visit














6 6Right eye Left eye
12 12Clock hours
9





6 6Right eye Left eye
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Appendix VIII. International 
classification of ROP
Stages (1 - 5)
1 Flat white demarcation line separates the 
vascular from the avascular retina
2 Ridge of fibrous tissue protrudes between 
the vascular and avascular retina
3 Blood vessels and fibrous tissue grow along 
the ridge and extend into the vitreous
4 Partial retinal detachment (4A – macula not 
involved; 4B – macula involved) is seen
5 Total retinal detachment has developed
Zones (I – III) and extent (clock hours)
I The most central zone, centred on the 
optic nerve with a radius equal to twice the 
distance from the disc to the fovea
II Extends concentrically from the edge of 
zone I to the nasal ora
III The remaining temporal crescent
In addition, extent is denoted in the number of clock hours 
affected (1 - 12)
12 12Clock hours
9





6 6Right eye Left eye
Plus disease
Blood vessels in the posterior pole appear tortuous and dilated. In 
addition, there may be vitreous haze, engorgement of iris vessels 
and poor dilatation of the pupil. The presence of plus indicates 
more severe ROP and rapid progression may follow.
Rush disease/AP-ROP (aggressive posterior ROP)
ROP in zone I with plus
Appendix IX. Neonatal nursery 




☐ Complications of therapy
☐ Risk of intraventricular haemorrhage (IVH)
☐ Risk of necrotising enterocolitis (NEC)
☐ Risk of ROP
☐ Risk of developmental delay
☐ ROP booking (if applicable) 
Date:
Venue:
☐ Risk of hearing loss
☐ Audiology booking (if applicable)
Date:
Venue:
☐ If dysmorphic, has mother been counselled 
☐ Discharge medication
☐ Date of follow-up
Date:
Venue:
☐ Discharge summary given to mother
☐ Road to Health Card summary 
☐ Six-week follow-up at local clinic for immunisation
☐ If retroviral disease (RVD)-exposed: 6-week polymerase 
chain reaction (PCR) and Bactrim prophylaxis and 
nevirapine (NVP) (if breastfeeding)
Doctor name and signature
Mother signature
